MINUTES OF ANNUAL GENERAL MEETING 2021
April 15, 2021 15:00 ET
|
Allarity Therapeutics A/S
On 15 April 2021 at 15:00 (CEST), the annual general meeting (the "General Meeting") of Allarity Therapeutics A/S, company registration (CVR) no. 28 10 63 51 (the "Company"), was held at c/o...
Allarity Therapeutics Submits Premarket Approval Application to U.S. FDA for DRP® Companion Diagnostic for Dovitinib
April 02, 2021 07:00 ET
|
Allarity Therapeutics A/S
- Submission precedes expected NDA filing for dovitinib in 2021 - Premarket Approval will allow U.S. marketing of DRP-Dovitinib as companion diagnostic to dovitinib Press release ...
Notice of Annual General Meeting
March 31, 2021 17:00 ET
|
Allarity Therapeutics A/S
31 March 2021 ALLARITY THERAPEUTICS A/S THURSDAY 15 APRIL 2021 AT 15:00 (CEST) The board of directors hereby convenes the Annual General Meeting of Allarity Therapeutics A/S, company...
Allarity Therapeutics Publishes its Annual Report for 2020
March 31, 2021 02:30 ET
|
Allarity Therapeutics A/S
Press Release Hørsholm, Denmark (31 March 2021) – Allarity Therapeutics A/S (“Allarity” or the “Company”) today announces the issuance of its Annual Report for 2020. The report is available as an...
Allarity Therapeutics plans fully guaranteed rights issue of approximately SEK 100 million
March 23, 2021 03:30 ET
|
Allarity Therapeutics A/S
- Proceeds will finance further development of three high-priority programs- Rights Issue is fully covered by subscription undertakings and guarantee commitments - The Company will discontinue the use...
Allarity Therapeutics Announces Positive Data from Preclinical Study of Dovitinib in Osteosarcoma
March 09, 2021 07:00 ET
|
Allarity Therapeutics A/S
- Treatment of animal osteosarcoma models with dovitinib increased the median survival time by 50 % as compared to control animals. Press release Hørsholm, Denmark (9 March 2021) – Allarity...
Allarity Therapeutics Initiates Phase 2 Trial of IXEMPRA® in Europe for the Treatment of Metastatic Breast Cancer
March 04, 2021 09:00 ET
|
Allarity Therapeutics A/S
Press release Hørsholm, Denmark (4 March 2021) – Allarity Therapeutics A/S (“Allarity” or the “Company”) today announced that it has enrolled the first patient in its European Phase 2...
Allarity Therapeutics Provides Update on Pre-Clinical Testing of Stenoparib’s Antiviral Activity Against New Variants of Coronavirus
February 24, 2021 10:19 ET
|
Allarity Therapeutics A/S
Press Release -Current testing follows preceding pre-clinical tests indicating efficacy of the novel PARP inhibitor stenoparib against SARS-Cov-2, the virus which is the origin of the B.1.1.7...
Allarity Therapeutics Draws Down the Fourth Tranche Under Its Convertible Note Agreement with Negma Group LTD and Park Partners GP
February 11, 2021 07:00 ET
|
Allarity Therapeutics A/S
Press Release Hørsholm, Denmark (11 February 2021) – Allarity Therapeutics A/S (“Allarity” or the “Company”) today announced that it has called upon the fourth tranche of SEK 10 million under its...
Allarity Therapeutics to test activity of its PARP inhibitor, stenoparib, as a potential therapy for new highly infectious Strain B.1.1.7 of Coronavirus
January 26, 2021 07:00 ET
|
Allarity Therapeutics A/S
Press Release Hørsholm, Denmark (26 January 2021) – Allarity Therapeutics A/S (“Allarity” or the “Company”) today announced plans to further test the antiviral activity of stenoparib, its PARP...